The Swiss pharma giant said it intends to hold on to Alcon’s $4.6 billion ophthalmic pharmaceuticals business under the Novartis Innovative Medicines umbrella, continuing a transition begun in January 2016. If consummated as expected during the first half of 2019, the separation of the remaining the surgical and vision care business would create a $7 billion enterprise with more than 20,000 employees, Novartis said.
IN CASE YOU MISSED IT
- Teva wins FDA approval for AirDuo Digihaler for asthma
- How human factors validation investigators identify user groups and populations
- Avoset to develop infusion pump with unnamed pharma giant
- Taris Bio, Bristol-Myers Squibb launch bladder cancer trial
- Nemaura bids for de novo clearance from FDA for SugarBEAT glucose monitor